Ribociclib for HR-positive HER2-negative Metastatic Breast Cancer

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

Breast Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Nagoya City University, Nagoya, Japan
Contact: Study coordinator (Kazuki Nozawa, MD) · ribociclib_IIS_CMIC@cmic.co.jp · +81-52-853-8020

Study leads

Hiroji Iwata, MD. PhD.
Study Chair
Nagoya City University

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Skipping Hormone Therapy in Low-Risk Early Breast Cancer

Breast Cancer (Early Breast Cancer)

Abroad (travel likely)RecruitingPHASE2

Angers, France · Avignon, France

Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast Cancer

Advanced Breast Cancer

Abroad (travel likely)RecruitingPHASE2

St Louis, United States · East Providence, United States

Study of Aerobic Training for People Receiving Treatment for Breast Cancer

Breast Cancer · Breast Carcinoma

Abroad (travel likely)RecruitingPHASE2

Basking Ridge, United States · Middletown, United States

Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer

Breast Cancer · Metastasis

Abroad (travel likely)RecruitingPHASE1, PHASE2

New York, United States · New York, United States